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Abstract
Motivation: Combination therapies have emerged as a powerful treatment modality to overcome drug resistance
and improve treatment efficacy. However, the number of possible drug combinations increases very rapidly with
the number of individual drugs in consideration, which makes the comprehensive experimental screening infeasible
in practice. Machine-learning models offer time- and cost-efficient means to aid this process by prioritizing the most
effective drug combinations for further pre-clinical and clinical validation. However, the complexity of the underlying
interaction patterns across multiple drug doses and in different cellular contexts poses challenges to the predictive
modeling of drug combination effects.
Results: We introduce comboLTR, highly time-efficient method for learning complex, non-linear target functions for
describing the responses of therapeutic agent combinations in various doses and cancer cell-contexts. The method
is based on a polynomial regression via powerful latent tensor reconstruction. It uses a combination of recommend-
er system-style features indexing the data tensor of response values in different contexts, and chemical and
multi-omics features as inputs. We demonstrate that comboLTR outperforms state-of-the-art methods in terms of
predictive performance and running time, and produces highly accurate results even in the challenging and practical
inference scenario where full dose–response matrices are predicted for completely new drug combinations with no
available combination and monotherapy response measurements in any training cell line.
Availability and implementation: comboLTR code is available at https://github.com/aalto-ics-kepaco/ComboLTR.
Contact: tianduanyi.wang@aalto.fi or juho.rousu@aalto.fi
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Combination therapies, involving two or more drugs, offer several
advantages over standard monotherapies, including higher treat-
ment efficacies and overcoming resistance mechanisms by modulat-
ing multiple targets and signaling pathways. This is especially
important in combating complex multi-factorial diseases, such as
cancer, and cardiovascular, neurological and autoimmune disorders.
Moreover, drugs in combination can often be administered in lower
individual doses which, in turn, results in reduced risk of adverse
reactions (Al-Lazikani et al., 2012; Pemovska et al., 2018). The
number of US Food and Drug Administration-approved drug combi-
nations has been continuously growing since the first approvals for
co-administration of drugs to treat nervous and respiratory system
disorders in 1940s (Das et al., 2018). Currently, most of the ongoing
research and development is focused on combinatorial therapies for
different cancer types (Pemovska et al., 2018). The development is,
however, very challenging as the number of possible pairwise combi-
nations increases very rapidly with the number of individual drugs,
not even mentioning the enormous size of the chemical universe that
could be explored (Reymond and Awale, 2012).
Computational approaches offer cost-effective means for large-
scale, fast and systematic pre-screening and prioritization of poten-
tial drug combinations for further experimental validation. Most of
the machine-learning models introduced to date and benchmarked
in crowd-sourced DREAM Challenge competitions (Bansal et al.,
2014; Menden et al., 2019) focus directly on the prediction of syner-
gistic drug combinations (Li et al., 2019; Preuer et al., 2018;
Sidorov et al., 2019; Tonekaboni et al., 2018; Yang et al., 2020).
Nonetheless, modeling the full dose–response matrices of drug pairs
offers more in-depth view of their complex response landscapes, and
allows to calculate different synergy metrics as a follow-up step.
This is important especially for translational applications, where
knowledge of optimal dose combination regions is often critical
(Ianevski et al., 2020; Tang et al., 2015).
Here, we introduce comboLTR, a new polynomial regression-
based framework for modeling anti-cancer effects of drug combina-
tions in various doses. We compare the performance of comboLTR
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to random forest (RF) and recently introduced method by our
groups, the comboFM method (Julkunen et al., 2020), using the
National Cancer Institute (NCI)-ALMANAC dataset (Holbeck
et al., 2017) generated by the US NCI. Both comboLTR and
comboFM exploit the fact that dose–response matrices of drug com-
binations can be represented as a higher-order tensor indexed by
drugs, drug concentrations and cell lines. To predict the response
values within the data tensor, a highly non-linear polynomial model
is needed in order to capture the multi-way interactions. To learn
the parameters of multivariate high-order polynomials, tensor fac-
torization approaches are effective. comboFM models the drug com-
bination effects by learning latent factors of the tensor using
factorization machines that estimate non-linear target functions
using symmetric polynomials and factorized parametrization
(Blondel et al., 2016). On the other hand, comboLTR is based on la-
tent tensor reconstruction (LTR) method (Szedmak et al., 2020),
which can be also considered as an alternative of factorization
machines, which extends the range of functions that can be learned
by removal of the assumption of the symmetry imposed on the poly-
nomials. Moreover, due to only linear dependence on the design
parameters separately, a straight, gradient-based algorithm can be
applied, which can also exploit advanced update rules, e.g. ADAM
(Kingma and Ba, 2015). As a consequence, comboLTR can process
much larger datasets than comboFM, in the number of both exam-
ples and features, with significantly reduced running time.
In summary, this article makes the following contributions.
• We introduce comboLTR, a new time-efficient framework for
modeling drug combination responses in cancer cell lines based
on a polynomial regression model where the function learning
problem is transformed into a tensor reconstruction problem,
with the tensor indexed by drugs, drug concentrations and cell
lines. The algorithm implements mini-batch data processing and
allows learning complex, highly non-linear target functions from
large-scale datasets with a constant memory complexity and lin-
ear running time in all important parameters (degree, rank, sam-
ple size and number of variables).
• We demonstrate that comboLTR provides highly accurate cell
line context-specific results under various prediction scenarios,
including more challenging and practical settings where dose–re-
sponse matrix predictions are made for (i) new drug combina-
tions with no available combination response measurements in
any cell line and (ii) when response measurements of individual
drugs are also lacking from the training data. Moreover, we
show that drug combination synergy scores can be recovered
with high accuracy based on the predicted dose–response
matrices.
• comboLTR can work with large feature sets, including chemical
descriptors and multi-omics cell line features, such as gene ex-
pression, copy number variation (CNV), CRISPR-Cas9 gene
knock-outs and proteomics data.
2 Materials and methods
2.1 Notation
In the text,  denotes the tensor product of vectors, h; i is the inner
product and jj jj is the norm in a Hilbert space H. The notation h; i is
also applied for the Frobenius inner product of tensors,  denotes the
pointwise product of tensors with the same shape of any order. 1m is
a vector of dimension m whose all components equal to 1. The set
1; . . . ;n for a given n is denoted by [n]. The matrix Du is a diagonal
matrix whose diagonal is equal to the vector u. Ai denotes the row i
of matrix A.
2.2 Data representation
In the learning problem, we have a sample of examples given by in-
put–output pairs S ¼ fðxi; yiÞji 2 ½m; xi 2 Rn; yi 2 Rnyg taken from
an unknown joint distribution of input and output sources. The
rows of the matrix X 2 Rmn contain the vectors xi, and similarly
the rows of Y hold the output examples, yi, for all i.
2.3 Background: learning polynomial regression
models











wj1 ;...;jnd xj1    xjnd ;
(1)
where w’s are the regression coefficients to be learned, n is the num-
ber of input variables and nd is the degree of the polynomial.
Polynomial regression models are known to have high represen-
tation power, capable of accurately representing continuous func-
tions with a fixed L1 norm-based tolerance. This fact allows us to
exploit the Stone–Weierstrass theorem and its generalizations
(Prenter, 1970) to approximate those functions by polynomials on a
compact subset with an accuracy not worse than a given arbitrary
small error.
However, estimating high-degree multivariate polynomial func-
tions presents challenges. An arbitrary multivariate polynomial




parameters, where n is the number of variables, and nd is the max-
imum degree of the polynomial. Thus, the complexity relating to the
size of the underlying parameter tensor is Oðnnd Þ, which grows ex-
ponentially in the number of parameters.
This exponential complexity in the polynomial degree presents
both statistical and computational challenges: there is often not
enough data to reliably estimate all the coefficients, and the expo-
nential time and space complexity forbids processing sufficiently
large training sets.
The key approach to tackle this exponential complexity in
higher-order factorization machines (HOFM) (Blondel et al., 2016;
Rendle, 2010) is a special representation of the coefficients as inner
products of factors: e.g. for the second order terms




where pi 2 Rnt encodes the participation of i’th variable in nt fac-
tors. For higher degree terms, the same is given by a generalized
inner product
Table 1. The general scheme of LTR-based regression
Prediction Learning
Given : T tensor; x
Output : y
pðxÞ ¼ hT;nd xi ) y
Given : fðyi; xiÞji 2 ½mg
Output : T tensor
mink;P
P








Note: Given an nd-order parameter tensor T and data point x, the prediction
entails computing an inner product between T and an nd-order tensor product
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wi1 ;...;im ¼ hpi1 ; . . . ; pim i ¼
Xnt
j¼1
pi1 ;j   pim ;j:
This factorized representation drastically reduces the number of
parameters to Oðnd  nt  nÞ (Blondel et al., 2016). The HOFM was
recently demonstrated to be able to accurately predict drug combin-
ation responses (Julkunen et al., 2020). However, HOFMs are con-
strained to symmetric polynomials, i.e. functions that are invariant
to permutation of features, which restricts the HOFM model as a
general regression model.
In this work, we follow an alternative approach for factorizing
the parameter representation, called LTR (Szedmak et al., 2020),
that starts from the full-order tensor representation of the unknown
regression coefficients and learning a factorization into rank-one
tensors (of full order) that optimizes the regression error (Table 1).
Importantly, the LTR model lifts the limitation of symmetricity of
the learned polynomial, and can therefore tackle a wider class of
learning problems.
2.4 Tensor-based representation of polynomial
functions
A polynomial function over the real numbers with degree nd and
with n variables can also be written in a compact form
pðxÞ ¼ hT;xndd¼1 xi; (2)
where T is a symmetric tensor of order nd, and with dimension
ndd¼1n. If the vector x is given in homogeneous form, extended with
a constant 1, then (2) covers all possible polynomials up to degree
nd. The tensor T can be given in a decomposed HOSVD form







s:t: jjpðdÞt jj ¼ 1; p
ðdÞ
t 2 Rn; t 2 ½nt:
(3)
This representation is generally not unique, see Lathauwer et al.
(2000) and de Silva and Lim (2008). By replacing T with its decom-














where we exploit the well-known identity connecting the inner prod-
ucts and the tensor products (Golub and Loan, 2013). This form
only consists of terms of scalar factors, where each scalar is the value
of a linear functional acting on the space X . This transformation
eliminates the difficulties, which arise in working directly with full
tensors. Observe that the function p is linear in each of the vector-
valued parameters, p
ðdÞ
t ; t 2 ½nt; d 2 ½nd.
We can further transform the polynomial representation (2.4)
into a form, which does not contain any reference to tensor product.
We have a following simple statement, which allows us to introduce
an additional factorization within the polynomial function to reduce
further the number of parameters.
Proposition 1.The polynomial function pðxÞ can be expressed only by







hpðdÞt ; xi ¼ kT ndd¼1P
ðdÞx; (4)





t , and k is a vector with components kt; t 2 ½nt .
Proof. The matrix-vector product PðdÞx yields a vector with components
ðhpð1Þt ; xi; . . . ; hp
ðndÞ
t ; xiÞ, and after a rearrangement, the original form can
be restored. h
2.5 LTR—basic form
comboLTR is built upon the LTR-based polynomial regression
method (Szedmak et al., 2020). LTR exploits the representation




















w:r:t: k;Q; PðdÞ; d 2 ½nd;
(5)
where Cp and Cq are penalty constants, and matrix Q projects the
vector given by the polynomial function of dimension nt into the
output space.
2.6 Reparametrization of the polynomial representation
In the LTR model, the predictor is implemented via a polynomial
function p acting on vectors x of dimension n. The parameter space
corresponding to matrices PðdÞ; d 2 ½nd has dimension ndntn which
is large enough to fit the polynomial to a non-linear function with
complex structure, but it requires a large sample to achieve a proper
estimation of those parameters. The LTR framework can be
extended to increase the flexibility, and in the same time, to reduce
the dimension of the parameter space. To this end, let the polyno-











where A is a pointwise activation function, and the matrix UðdÞT
is a linear transformation projecting the original input vector
into a space with lower dimension, nk, for each d 2 ½nd. That
projection can enforce a bottleneck within the polynomial func-
tion. This modification preserves the linear dependence on the
matrix valued parameters. The expression /ðxÞ ¼ AðUðdÞTxÞ
might be viewed as a layer of a neural network. The main differ-
ence is that the layers within the LTR are joined by a polynomial
function in a parallel way instead of being connected
sequentially.
The following table summarizes the matrices describing the
extended LTR problem.
The parameter k corresponds to the singular values of the tensor
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The extended LTR problem now takes the following form
(7)
where Ck is a penalty constant relating to the scale factor k.
2.7 Projection-based algorithm
The optimization problem of (7) is solved by an iterative algorithm,
which maintains the constrains imposed on the rows of parameter
matrices by projecting them onto the unit sphere.
• Step 1 Let ‘ ¼ 0, and the learning speed be 0 < c < 1.
• Step 2 Initialize the parameters
kðuÞ½‘ ¼ 1n; k½‘ ¼ 1nt ;
UðdÞ½‘jk; VðdÞ½‘tk; Q½‘ts  Nð0; 1Þ;
d 2 ½nd; j 2 ½n; k 2 ½nk; t 2 ½nt; s 2 ½ny;
(8)
where Nð0; 1Þ is the standard normal distribution.
• Step 3 Normalize the rows of the optimization parameters by
L2 norm. Only the vector k½‘ will be unnormalized.
• Step 4 Set the scale value for the unnormalized vector k by

















• Step 5 Compute the value of the objective function of the
extended LTR problem given by (7)
hðuvÞ½‘ ¼ jjY F½‘Dk½‘Q½‘jj2: (11)
• Step 6 Compute the partial gradients of hðuvÞ by applying (15),
rUðdÞhðuvÞ; rVðdÞhðuvÞ;d 2 ½nd;
rkðuÞhðuvÞ; rkhðuvÞ; rQhðuvÞ:
(12)
• Step 7 Update the parameters
kðuÞ½‘þ 1 ¼ kðuÞ½‘ þcrkðuÞ ½‘hðuvÞ;
k½‘þ 1 ¼ k½‘ þcrk½‘hðuvÞ;
UðdÞ½‘þ 1 ¼ UðdÞ½‘ þcrUðdÞ ½‘hðuvÞ; d 2 ½nd;
VðdÞ½‘þ 1 ¼ VðdÞ½‘ þcrVðdÞ ½‘hðuvÞ; d 2 ½nd;
Q½‘þ 1 ¼ Q½‘ þcrQ½‘hðuvÞ:
13
• Step 8 Normalize the optimization parameters in L2 norm.
• Step 9 ‘ ¼ ‘þ 1.
• Step 10 Go to Step 5.
For large-scale applications, the above algorithm is further
extended by partitioning the training examples into mini-batches,
and processing them sequentially. A single run of the cycle based on
mini-batches is taken as an epoch, and repeated. To reduce the vari-
ance caused by the partition, a momentum-based update can be
applied, e.g. Nestorov Accelerated Gradient method, or the ADAM
method frequently applied for Deep Neural Networks (Kingma and
Ba, 2015; Nesterov, 2005; Polyak, 1964).
2.7.1 Gradients
Let the matrix HðdÞ 2 Rmnk contain the partial derivatives of the ac-
tivation function with respect to the components of the matrix
XDkðUÞU
ðdÞ, where we exploited that the activation function is a
pointwise map of the matrix in its argument. We exploit the follow-
ing expressions to shorten the gradient formulas
Fnd ¼ ndb¼1;b6¼dA
ðbÞVðbÞT ;













































ðFTE  k1Tny Þ:
(15)
2.8 Dataset
In order to evaluate the performance of comboLTR, we used the
drug combination responses in human cancer cell lines from the
NCI-ALMANAC study (Holbeck et al., 2017). To exploit more
data sources, especially multi-omics profiles of the cancer cell lines,
we filtered the data to include only the cell lines for which gene ex-
pression, CNV, CRISPR-Cas9 gene knock-outs and proteomics data
were available. The resulting dataset consisted of 828 324 response
measurements of 5035 drug combinations and 15 396 monothera-
pies in 19 cancer cell lines originating from 9 tissue types. Each drug
combination has been screened using 44 dose–response matrix de-
sign. The response measurements are given in the form of percentage
growth of the cell lines with respect to a control. The distribution of
our drug combination response dataset in 19 cell lines was identical
to the distribution of all drug combination responses from the NCI-
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Tensor index features Auxiliary chemical and multi-omics features
Fig. 1. Illustration of the drug combination response tensor and its feature represen-
tation. (a) Drug combination responses form a fifth-order tensor indexed by drugs,
their concentrations and the cell lines. (b) The drug combination response tensor
can be flattened into a tensor index featurematrix via one-hot encoding and accom-
panied by chemical and biological information
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2.9 Feature representation
Each drug combination response is uniquely determined by five
components, i.e. two drugs, their concentrations and a cell line.
Such drug combination responses indexed by quintuplets form a
fifth-order tensor (Fig. 1a). To flatten the higher-order tensor into a
feature matrix, each such quintuplet is assigned a unique codeword
by one-hot encoding the five components. The resulting tensor index
features are similar to ones used in recommender systems (e.g. rec-
ommending movies to users). In addition to the tensor index fea-
tures, the feature matrix also consists of auxiliary features, such as
chemical and cell line descriptors, to include more available data
sources (Fig. 1b).
As for chemical features, we used standard MACCS fingerprint,
which consists of 166 chemical substructures. Each drug was
matched with the substructures and represented as a binary feature
vector describing whether a substructure was contained in the drug.
Substructures present in all or none of the drugs were removed from
the feature set, leaving 148 substructures in the end. For cell line fea-
tures, multi-omics data including gene expression, CNV, CRISPR-
Cas9 gene knock-outs and proteomics data were incorporated from
DepMap data portal (Ghandi et al., 2019; Meyers et al., 2017;
Nusinow et al., 2020) to represent cell lines. Due to the large size of
multi-omics data, in this case, more than 70 000 features, only 1%
of the omics features with the highest variance across the 19 cell
lines were selected, which resulted in 191 gene expression features,
276 CNV features, 174 CRISPR-Cas9 gene knock-out features and
69 proteomics features.
3 Results
We evaluated the performance of comboLTR in four practical pre-
diction scenarios (Fig. 2):
• Filling in the gaps in partially measured dose–response matrices
(S1).
• Prediction of complete dose–response matrices of new drug com-
binations with no available combination response measurements
in any cell line, monotherapy response values present for both
drugs (S2).
• Prediction of complete dose–response matrices of new drug com-
binations with no available combination and monotherapy re-
sponse measurements in any cell line (S3).
Based on the results by Julkunen et al. (2020), predicting dose–
response matrices of completely new drug combinations is the most
challenging task from the above. Thus, we aimed to test our
comboLTR framework under the difficult prediction scenario S2,
and furthermore, under even more challenging prediction scenario
S3. As shown in Figure 2, S3 has the least information available for
a drug combination, since even monotherapy responses of single
drugs are not present. Scenario S1 forms a relatively easy task, and
thus it was considered as the reference prediction scenario. For
completeness, in addition to these three scenarios, following
Julkunen et al. (2020), we also considered the scenario of predicting
dose–response matrices of previously untested drug–drug–cell line
triplets in the case where the response matrices of the same drug
combination in other cell lines are known. However, as it was not
our main focus in this study, the results for this prediction scenario
are included in the Supplementary material only (Supplementary
Tables S1 and Fig. S2). We also benchmarked the performance of
comboLTR against RF and comboFM.
3.1 Model optimization via 5-fold cross validation
We applied 5-fold cross validation (CV) in all prediction scenarios
in order to tune the model parameters and evaluate the predictive
performance. In scenario S1, for each dose–response matrix, com-
bination responses were randomly selected into test sets. In scenario
S2, dose–response matrices of certain drug combinations in all cell
lines were randomly selected into test sets. All monotherapy
responses were kept in the training sets for S1 and S2 prediction
scenarios. S3 is similar to S2 but with all monotherapy responses
excluded from training set.
Based on our previous research, the degree of the polynomial
function in comboLTR was set to five to model the interactions be-
tween the five components, i.e. two drugs, their concentrations and
the cell line, which uniquely determine each drug combination re-
sponse in the drug combination response tensor. A total of 20 drugs
were randomly selected to subsample the full dataset for comboLTR
parameter tuning. The subsampled dataset contained 31 095 re-
sponse measurements of 208 drug combinations and 1901 mono-
therapies in 19 cell lines. The subsampled drug combination
responses had almost identical distribution as our full dataset and
also the whole dataset from NCI-ALMANAC study (Supplementary
Fig. S1). Once parameters were determined, the performance of the
model was evaluated using 5-fold CV on the full dataset, with the
exception that the subsampled dataset was present in the training set
only. comboLTR was evaluated using 5-fold CV for up to the 9th
order with rank 200. Only very slight overfitting was observed in
the highest order models.
We used a python implementation of RF from scikit-learn
(Pedregosa et al., 2011) and its default parameters for training and
prediction. Parameters for comboFM were taken from the original
publication (Julkunen et al., 2020). In addition to fully evaluate the
predictive performance of comboFM and RF, in the most challeng-
ing prediction scenario S3, their parameters were also optimized
using the subsampled drug combination responses. The models with
optimal parameters were then applied on the full dataset in the pre-
diction scenario S3.
3.2 Prediction of anti-cancer effects of drug
combinations
We used different feature combinations to train comboLTR model,
as shown in Table 2. Since the one-hot encoded tensor indices are
only positional features of the quintuplets, MACCS fingerprint and
multi-omics data were used as auxiliary features to provide add-
itional information on drugs and cell lines. In scenario S1, when fill-
ing in the gaps in partially measured dose–response matrices, the
performance difference between feature combinations was negli-
gible. Using only tensor index features resulted in the Pearson correl-
ation between predicted and measured responses of 0.915, whereas
adding auxiliary chemical and biological features led to the Pearson
correlation of 0.922. However, in scenarios S2 and S3, when pre-
dicting the responses of completely new drug combinations, even
without monotherapy responses present, adding auxiliary features
clearly increased the prediction performance. In particular, in the
most challenging scenario S3, using tensor indices only and add-
itionally including auxiliary features, resulted in the Pearson correla-
tions of 0.893 and 0.915, respectively. With the advantage of
handling large feature vectors, comboLTR can harness data from
different sources for the improved prediction performance. Thus,
tensor index features, chemical and multi-omics auxiliary features
were used in all further experiments.
(a) (b) (c)
Fig. 2. Illustration of different drug combination response prediction scenarios. (a)
Filling in the gaps in partially measured dose–response matrices (S1); predicting
dose–response matrices of new drug combinations (b) with monotherapy responses
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We used RF and comboFM as comparison methods in all predic-
tion scenarios. Scatter plots of the predicted and measured drug
combination responses are shown in Figure 3. As expected, in scen-
ario S1, all three methods achieved comparable prediction perform-
ance. Pearson correlations for comboLTR, comboFM and RF were
0.922, 0.915 and 0.923, respectively. However, the difference in the
performance of the methods became clearly visible in the most chal-
lenging and practical scenarios of predicting dose–response matrices
of completely new drug combinations with and without monother-
apy responses available (S2 and S3). Notably, under scenario S3,
comboLTR, with a Pearson correlation of 0.915, clearly outper-
formed comboFM and RF (Pearson correlations of 0.878 and
0.896, respectively). It demonstrates that monotherapies play an
important role in predicting higher-order interactions by comboFM.
On the other hand, comboLTR produced more accurate predictions
with fewer experimental measurements, which makes comboLTR
more practical and applicable in recommending combination
therapies.
To further study the prediction performance of those three meth-
ods, we investigated Pearson correlations for drug pairs in different
drug classes and cell lines from different tissue types (Fig. 4). In gen-
eral, comboLTR showed higher average Pearson correlation in most
tissue types and drug classes. It was also corroborated by the violin
plots that comboLTR shows better and more stable prediction per-
formance across different drug classes and tissue types, particularly
in the more challenging scenarios S2, and even S3 where less infor-
mation was available.
Next, we evaluated the performance of the methods in quantify-
ing the level of synergy and identifying highly synergistic drug com-
binations based on the predicted dose–response matrices. To
calculate the synergy scores, we applied the NCI ComboScore intro-
duced along with the NCI-ALMANAC dataset (Holbeck et al.,
2017). Scatter plots and Pearson correlations between the NCI
ComboScores calculated based on the complete measured and pre-
dicted dose–response matrices of the three methods are shown in
Supplementary Figure S3. RF performed particularly well in the sim-
plest scenario S1, but comboLTR clearly outperformed the other
two methods in the more challenging scenarios, e.g. with a Pearson
correlation of 0.67 compared to 0.57 (comboFM) and 0.46 (RF), in
the S3 scenario. We also conducted discrimination analyses using
the precision-recall (PR) curves (Supplementary Fig. S4) and receiver
operating characteristic curves (Supplementary Fig. S5) to further
evaluate the model performance in classifying drug combinations as
synergistic versus non-synergistic with varying thresholds for syn-
ergy, in the three prediction scenarios. comboLTR showed very
competitive performance in discriminating highly synergistic drug
combinations across several top-% synergy thresholds in the most
challenging prediction scenarios. For example, in scenario S3, the
areas under the PR curve at a synergy threshold of 5% for
comboLTR, comboFM and RF were 0.25, 0.16 and 0.12, respective-
ly (Supplementary Fig. S4).
To investigate the importance of multi-omics features, contribu-
tion of each type of omics data to the model performance was eval-
uated by ‘leave one type of omics data out’ and ‘adding only one
type of omics data’ 5-fold CVs (Table 3). First, from the feature set
comprising tensor indices, MACCS fingerprints and multi-omics
data, each type of omics data were excluded to test their contribu-
tion to the predictive performance. Then, the predictive performance
was also evaluated by including each type of omics data into the fea-
ture set, on top of tensor indices and MACCS fingerprints. The pre-
diction performance was relatively stable when including or
excluding certain types of omics data.
To investigate the importance of individual features, after the
model was trained, each feature column was randomly permuted 20
times, and the average Pearson correlation difference between the
models with original and permuted feature matrices was calculated
as a measure to evaluate individual feature contribution to the pre-
dictive performance (Supplementary Fig. S6.). Weights of features
from trained comboLTR model were also extracted and plotted in
the form of a heatmap of L2-norm of each feature set, including
MACCS fingerprints, gene expression, CNV, CRISPR-Cas9 gene
knock-outs and proteomics data (Supplementary Fig. S6). In general,
the most weight has been placed on tensor indices, while MACCS
fingerprints and multi-omics data had only a relatively minor contri-
bution to the model accuracy.
4 Discussion
Drug combinations are emerging as a powerful treatment modality
to combat complex multi-factorial disorders, including cancer.
Machine-learning models can significantly speed-up the search for
effective drug combination therapies by systematically prioritizing
the most promising combinations for further experimental valid-
ation. Using existing drug combination response data, we developed
comboLTR to efficiently recommend combination therapies for can-
cer. Table 2 shows that comboLTR produces accurate and stable
predictions even without monotherapy responses present in the
training data. Monotherapy responses, which contain individual
drugs tested in different cancer cell lines in various concentrations,
are also costly and time-consuming to obtain in the lab. Without
such limitation, comboLTR is more applicable and practical, espe-
cially in clinical research.
We compared the performance of comboLTR to RF and recently
introduced comboFM method. Both comboLTR and comboFM are
based on polynomial regression. A performance difference between the
two methods in prediction scenario S3, where dose–response matrices
of completely new drug combinations without monotherapy responses
are inferred, could be due to different forms of polynomial functions to
be learned. In comboLTR, a complete polynomial of degree nd is used,
while in comboFM, it is restricted to the symmetric polynomials. Since
the monotherapies induce asymmetry in the drug representation, a
Table 2. Performance of comboLTR, comboFM and RF under different prediction scenarios and using different features
Features Method S1 S2 S3
Tensor indices comboLTR 0.915 6 0.009 0.894 6 0.002 0.893 6 0.003
comboFM 0.920 6 0.010 0.914 6 0.003 0.907 6 0.004
RF 0.886 6 0.019 0.853 6 0.010 0.858 6 0.010
Tensor indices þMACCS comboLTR 0.921 6 0.010 0.908 6 0.003 0.910 6 0.003
comboFM 0.923 6 0.012 0.923 6 0.005 0.913 6 0.005
RF 0.921 6 0.016 0.872 6 0.009 0.894 6 0.005
Tensor indices þ multi-omics comboLTR 0.908 6 0.014 0.909 6 0.007 0.911 6 0.005
comboFM 0.910 6 0.027 0.904 6 0.014 0.870 6 0.064
RF 0.895 6 0.019 0.859 6 0.010 0.865 6 0.010
Tensor indices þMACCS þ multi-omics comboLTR 0.922 6 0.011 0.914 6 0.006 0.915 6 0.005
comboFM 0.915 6 0.012 0.889 6 0.024 0.878 6 0.064
RF 0.923 6 0.015 0.873 6 0.009 0.896 6 0.005
Note: Pearson correlations between predicted and measured drug combination responses, reported as averages across five CV folds 6 SDs.
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method which can cover the full range of possible polynomials has
higher probability to combine both the symmetric and asymmetric rela-
tions. The symmetry restriction of comboFM also eliminates the mono-
mials with higher-order occurrences of the polynomial variables, which
could also reduce further the range of functions to be approximated.
Thus, it could be hypothesized that comboFM may rely more on lower-
order interactions, such as monotherapy responses. The lack of such
lower-order interaction information results in a performance drop of
comboFM in the prediction scenario S3. We note that comboFM is a bit
more competitive without using the MACCS and multi-omics features
than when using them, which may be at least in part caused by the sym-
metricity of the polynomials with respect to the variables. Specifically,
the tensor indices and the MACCS and multi-omics features are treated
alike by comboFM, but not comboLTR. Tensor indices, however, do
not allow any explanation of the predictions in terms of underlying bio-
logical functions or processes, and hence models relying solely on them
might not be preferable in practical use.
Furthermore, in practical clinical applications, identification of
synergistic drug combinations is of high interest. Importantly,
comboLTR outperformed comboFM and RF in the most challenging
prediction scenarios also in the task of discriminating highly syner-
gistic drug combinations based on the predicted complete dose–re-
sponse matrices and when using a range of different top-% synergy
thresholds (Supplementary Figs S4 and S5).
Since CV experiments were run on different machines, the lon-
gest running time and median memory across all prediction scen-
arios were recorded (Table 4). Compared to comboFM, which also
learns from higher-order interactions, comboLTR is significantly
more time-efficient, especially in handling large feature vectors
(Table 4). When training models using the full dataset with tensor
index features, MACCS fingerprints and multi-omics information,
only 3.1 h were needed for a 5-fold CV using comboLTR, whereas
comboFM took 39 h. Most of the memory was used for storing the
data.
Fig. 3. Predictive performance of comboLTR, comboFM and RF in three drug combination response prediction scenarios. Scatter plots between the predicted and measured
dose–dependent drug combination effects in the form of %-growth of cancer cell lines. The predictions were made under three scenarios of (a) filling in the gaps in partially
measured dose–response matrices, inferring dose–response matrices of completely new drug combinations with (b) and without (c) monotherapy responses available. Root
mean squared error, Pearson correlation and Spearman correlation are reported as averages 6 SDs over five CV folds. Diagonal line and linear fit are also displayed in each










ulib user on 04 O
ctober 2021
In this work, genomic, transcriptomic and proteomic data were
used to provide additional information on cancer cell lines. The






S1: Filling in the gaps in partially measured dose-response matrices
S2: Predicting dose-response matrices of new drug combinations
S3: Predicting dose-response matrices of new drug combinations w/o monotherapy responses
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Fig. 4. Predictive performance of comboLTR, comboFM and RF across tissue types and drug classes in three drug combination response prediction scenarios. Violin plots were
used to characterize Pearson correlations of predicted and measured drug combination responses across tissue types (a–c) and drug classes (d–f). Note that the order of tissue
types and drug classes in the legends corresponds to their order in the violin plots
Table 3. The 5-fold CV results of comboLTR, in the form of Pearson
correlations, when leaving one type of omics data out or including
only one type of omics data, compared with using the full multi-
omics data, on top of tensor indices and MACCS fingerprints
Multi-omics feature combination S1 S2 S3
Full multi-omics 0.922 0.914 0.915
Excluding gene expression 0.921 0.912 0.914
Excluding CNV 0.921 0.916 0.914
Excluding CRISPR knock-out 0.921 0.914 0.913
Excluding proteomics 0.920 0.914 0.914
Using only gene expression 0.921 0.912 0.911
Using only CNV 0.921 0.911 0.910
Using only CRISPR knock-out 0.921 0.909 0.911
Using only proteomics 0.921 0.910 0.910
Table 4. The time (h) and memory (GB) usage of comboLTR,
comboFM and RF in 5-fold CV
Time (h)/memory (GB)
Features comboLTR comboFM RF
Tensor indices 1.1/24 1.2/20 1.2/24
Tensor indices þMACCS 2.1/35 5.9/35 0.4/38
Tensor indices þ multi-omics 3.2/44 31.5/63 5.6/54
Tensor indices þMACCS þ
multi-omics
3.1/74 39.0/73 2.1/74
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measurements form a comprehensive molecular network. For ex-
ample, CNVs affect expression of genes which, together with post-
translational modifications, influence the quantity of proteins. Since
the full multi-omics dataset included over 70 000 features, we
reduced the dimensionality of the data by selecting only 1% of each
type of omics data as auxiliary descriptors characterizing cell lines
(see Section 2.7).
As shown together in Tables 2 and 3 and Supplementary Figure
S6, the performance increase brought by integrating multi-omics
data into the model was only modest. This phenomenon could be
due to that only 1% of the full multi-omics dataset was taken into
account, which represented only a small part of the cell’s character-
istics. Besides, the complex interactions of the molecular network
were not taken into consideration in this experiment. For example,
different drugs at various concentrations may result in multiple per-
turbations to the molecular network, which will change the cellular
phenotype into diverse states. The lack of integrating such compli-
cated interactions could lead to less relevant features selected for
predicting drug combination responses. One of our future aims is to
select cell features based on their connections with tested drug com-
binations, e.g. to assign weights to features based on their inter-
action strength with drugs.
On the other hand, MACCS fingerprint had slightly higher associ-
ated feature weights and performance increase, when compared to the
multi-omics features. MACCS fingerprint characterizes drugs by the
presence or absence of specific chemical substructures. As shown in
Supplementary Figure S7, different drugs in our dataset have common
substructures due to the limited number of substructures defined by
MACCS fingerprint. Such property is expected to be helpful especially
in scenarios S2 and S3 where new drug combinations were predicted. It
could be speculated that more weight would be placed on the multi-
omics features in the scenario of predicting drug combination responses
in the cell lines outside of the training data.
5 Conclusions
In this work, we have put forward a novel approach for predicting
responses of cancer drug combinations. Our method, comboLTR, is
based on representing high-degree polynomial regression models
through learning a factorization of the parameter tensor containing the
unknown regression coefficients. We demonstrated the competitive pre-
dictive performance and time efficiency of the comboLTR method on
the large NCI-ALMANAC dataset (Holbeck et al., 2017).
The results indicate that comboLTR is a practical tool for predic-
tion and prioritization of new drug combinations for pre-clinical
and clinical evaluation. The ability to predict full dose–response
matrices enables a detailed exploration of drug response landscapes
and application of different synergy models.
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